Previous 10 | Next 10 |
2023-05-10 11:03:07 ET Pieris Pharmaceuticals, Inc. (PIRS) Q1 2023 Earnings Conference Call May 10, 2023, 08:00 AM ET Company Participants Thomas Bures - CFO Stephen Yoder - President and CEO Shane Olwill - Chief Development Officer Conference Call Particip...
2023-05-10 07:11:28 ET Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): Q1 GAAP EPS of -$0.18 misses by $0.04 . Revenue of $1.94M (-82.3% Y/Y) misses by $4.57M . For further details see: Pieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, rev...
COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDT Enrollment for elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to progress with topline clinical data anticipated by mid-2024; successful safety review completed for 10 mg dose cohort...
2023-05-09 11:38:25 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) is scheduled to announce Q1 earnings results on Wednesday, May 10th, before market open. The consensus EPS Estimate is -$0.09 (-28.6% Y/Y) and the consensus Revenue Estimate is $6.51M (-40.8% Y/Y). Over the...
BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today announced the ...
BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer and other indications, today announced tha...
2023-04-17 14:33:27 ET Pieris Pharmaceuticals ( NASDAQ: PIRS ) added ~11% on Monday after announcing the latest data for its investigational bispecific cinrebafusp alfa from a mid-stage trial for patients with HER2-positive gastric cancer at the ongoing annual meeting of the A...
BOSTON, MA / ACCESSWIRE / April 17, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the...
2023-03-29 15:41:29 ET The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Pieris Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation
2023-03-29 15:40:06 ET Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Results Earnings Conference Call March 29, 2023, 08:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Stephen Yoder - President and Chief Executive Officer...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 millio...